Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Income Before Tax

Profit after all operating and non-operating items but before income tax.

Alumis Inc. Common StockNASDAQ: ALMS

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax turns negative

Q2 FY2026 income before tax was -$143.98M, compared with $50.76M a year earlier. Trailing-twelve-month income before tax was -$440.71M.

Context

  • Income before tax amounted to 1047.3% of revenue in FY2025.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$143.98M or moves back toward the trailing-twelve-month quarterly average of -$110.18M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$143.98M-54.7% QoQ
Last fiscal yearDec 2025
-$251.89M+14.4% YoY
LTMJun 2026
-$440.71M-86.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-383.6%——
1 year+14.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(251.89M) USD
Year-over-year change
+14.4%

Income Before Tax vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -86.7% is the 8th highest of 10, against a peer median of +1.7%.
  • Income before tax amounts to 5957.2% of revenue for ALMS, versus a peer median of 832.6%.
ALMS Competitors
Income Before Tax for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$121.97M USD+219.9%—40.7%
TLSATiziana Life Sciences LtdFY2025-$18.43M USD-10.1%——
ANABAnaptysBio, Inc.LTM Mar 2026-$26.63M USD+81.1%—11.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$27.37M USD+52.6%——
IFRXInflaRx N.V.LTM Mar 2026-€42.81M EUR+1.7%—145945.5%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€46.26M EUR-285.2%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.57M USD-215.6%—143340.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$87.07M USD-34.3%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$440.71M USD-86.7%—5957.2%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ALMS) —+1.7%—832.6%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.